Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.

    • Authors:
    • Ming Bai
      Fourth Military Medical University
      China
      Na Song
      a Institute of Evolution and Marine Biodiversity
      China
      Dr. Xiaofang Che, MD, PhD
      China Medical University
      Shenyang, Liaoning | China
      Xiaoxun Wang
      Anhui Key Laboratory of Chemo-Biosensing; Key Laboratory of Functional Molecular Solids
      Xiujuan Qu
      The First Hospital of China Medical University
      Shenyang Shi | China
      Yunpeng Liu
      The First Hospital of China Medical University
      China
    Cell Biol Int 2017 Dec 22. Epub 2017 Dec 22.
    Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
    The ATM and Rad3-related (ATR) /checkpoint kinase 1 (Chk1) pathway plays a pivotal role in DNA damage sensor and modulating homologous recombination. Recently, emerging evidence demonstrated that Chk1 phosphorylation was associated with chemotherapy and radiotherapy resistance. In this study, we explored the effect of ATR/Chk1 pathway on regulating lapatinib sensitivity in human epidermal growth factor receptor-2 (HER2)-positive gastric cancer cell lines. We selected two HER2-positive gastric cancer cell lines, and NCI-N87 cells exhibited higher sensitivity than MKN7 cells. Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells. In NCI-N87 cells, lapatinib induced G1 arrest and reduced Chk1 phosphorylation through inhibiting the expression of DNA topoisomerase 2-binding protein 1 (TopBP1). While in MKN7 cells, no significant cell cycle transition was found and phosphorylated Chk1 was mildly upregulated. Inhibition of Chk1 phosphorylation enhanced the lapatinib sensitivity of MKN7 cells, which was shown by potentiated anti-proliferative effect, G1 arrest, downregulation of phosphorylated AKT and ERK along with aggravated DNA damage. In addition, increased Chk1 phosphorylation in NCI-N87 cells attenuated lapatinib-induced anti-proliferative effect and G1 arrest, and abrogated reduced phosphorylated AKT and ERK. Taken together, our study provides a novel mechanism for regulating lapatinib sensitivity in HER-2 positive gastric cancer cells, suggesting a new strategy in clinical treatment.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1002/cbin.10922DOI ListingPossible

    Similar Publications

    The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Cancer Lett 2008 Dec 6;272(2):296-306. Epub 2008 Sep 6.
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea.
    HER2 overexpression is observed in 5-25% of gastric cancers. Lapatinib is a dual inhibitor of the epidermal growth factor receptor and HER2 tyrosine kinase. We examined the antitumor effect of lapatinib in gastric cancer cell lines. Read More
    MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Mol Cancer Ther 2012 Mar 11;11(3):660-9. Epub 2012 Jan 11.
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
    HER2 amplification is found in more than 15% of gastric cancers and is associated with poor clinical outcome. Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating HER2(+) cancer cells. However, several studies have shown that activation of alternative receptor tyrosine kinases can mediate resistance to HER-targeted therapy. Read More
    A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells.
    Mol Cell Biochem 2017 Dec 1;436(1-2):29-38. Epub 2017 Jun 1.
    Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
    The ATR/checkpoint kinase 1 (Chk1) pathway plays an essential role in modulating the DNA damage response and homologous recombination. Particularly, Chk1 phosphorylation is related to cancer prognosis and therapeutic resistance. Some receptor tyrosine kinases participate in the regulation of Chk1 phosphorylation; however, the effect of hepatocyte growth factor (HGF) on Chk1 phosphorylation is unknown. Read More
    Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Clin Cancer Res 2010 Mar 23;16(5):1509-19. Epub 2010 Feb 23.
    Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, California 90404, USA.
    Purpose: HER2 amplification occurs in 18% to 27% of gastric and gastroesophageal junction cancers. Lapatinib, a potent ATP-competitive inhibitor simultaneously inhibits both EGFR and HER2. To explore the role of HER family biology in upper gastrointestinal cancers, we evaluated the effect of lapatinib, erlotinib, and trastuzumab in a panel of molecularly characterized human upper gastrointestinal cancer cell lines and xenografts. Read More